A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274

A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274

This is a 3-part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JNJ-48816274 in healthy participants after administration of single and repeated doses, and to evaluate its potential effectiveness for treating insomnia.

Inclusion Criteria:

• Must be healthy as assessed by medical history and safety evaluations performed at screening
• Has a body mass index between 18 and 30 kilogram per square meter (kg/m2) and body weight not less than 50 kg
• Must be willing and able to abide by the prohibitions and restrictions of the study, including requirements for contraception
• Women must not be of childbearing potential by either being postmenapausal or permanently sterilized
• Part 2 Only: Maintains a regular sleep-wake cycle as measured by sleep diaries and a watch that measures activity
• Has a habitual (majority of days) bedtime and duration of sleep that meet the study requirements

Exclusion Criteria:

• Current or history of clinically significant medical or psychiatric illness, or recent major surgery or blood loss/donation
• Any current sleep-wake disorder, recent night shift work, or history of insomnia within the last 5 years
• Man who has a pregnant female partner
• Woman who is breastfeeding
• Is participating or has participated within the last 3 months in a study with an investigational drug or medical device
• Tests positive or has a history of human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or other active liver disease
• Drug or alcohol abuse within the last 5 years, nicotine use within the last 3 months, or tests positive for alcohol, drugs of abuse, or nicotine
• Routinely consumes an excessive amount of caffeine